Antisense is a technique used in genetic research to inhibit gene expression.

An allele is one of two or more versions of a gene that are found at the same location on a chromosome.

One can elucidate the entire antibody sequence by utilizing a known Complementarity-determining region (CDR) sequence in combination with the accessible Patsnap Bio Sequence Database.

The patent and literature contain sequences of nucleic acids containing N and protein sequences containing X. I'm interested in reducing the risk of missing such sequences. Is there a recommended database where I can search for these sequences?

In the AAV field, common inventions involve the replacement and combination of expression-related gene regulatory elements.

More than one encoding rule for CDR sequences is required to reduce the risk of missing FTO sequences in antibody searches.

The October release of the Patsnap Bio Sequence Database provides a plethora of enhancements in order to improve your searching experience and elevate the efficiency of your FTO review.

EMBL-EBI offers a plethora of widely trusted online tools for sequence alignment. Moreover, our emphasis is laid on a profound recommendation: a user-friendly, commercial Patsnap Bio Sequence Database sequence alignment tool, which commendably offers free registration.

In the rapidly escalating field of biological research, the importance of intellectual property (IP) has never been more critical. With biological sequences becoming paramount in the biotech and pharmaceutical sectors, the advent of a convenient, comprehensive patent search database is indeed a significant breakthrough.

To undertake a detailed exploration of sequence modifications and comprehend the associated specific patent information, we propose utilizing the Patsnap Bio sequence database. Boasting an extensive archive of patent literature and affiliated sequence data, this bio-database forms an invaluable tool for a thorough investigation.

Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved remarkable success in some hematological malignancies in preclinical and clinical trials.

Kadcyla is an antibody-drug conjugate (ADC) used as a single-agent treatment for HER2-positive metastatic breast cancer patients. The article introduces the specific operational methods for patent retrieval of the ADC drug Kadcyla.